The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
 
Isabelle Ray-Coquard
No Relationships to Disclose
 
Ioana Braicu
Honoraria - Fuji Pharma; Roche Pharma AG
 
Regina Berger
No Relationships to Disclose
 
Sven Mahner
Honoraria - AstraZeneca; Debiopharm Group; GlaxoSmithKline; Janssen-Cilag; MSD; PharmaMar; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; MSD; Roche Pharma AG
Research Funding - Roche Pharma AG
 
Jalid Sehouli
Honoraria - AstraZeneca; Roche Pharma AG
Consulting or Advisory Role - Roche Pharma AG
Research Funding - GlaxoSmithKline; Lilly; Roche Pharma AG
 
Alain G Zeimet
No Relationships to Disclose
 
Eric Pujade Lauraine
Honoraria - AstraZeneca; Roche Pharma AG
 
Philippe Alexandre Cassier
Honoraria - GlaxoSmithKline; Novartis
Consulting or Advisory Role - Blueprint Medicines; Novartis; SERVIER
Research Funding - AstraZeneca; Celgene; Genentech; Novartis; Roche Pharma AG
 
Utemartha Moll
No Relationships to Disclose
 
Hanno Ulmer
No Relationships to Disclose
 
Karin Leunen
No Relationships to Disclose
 
Christian Marth
No Relationships to Disclose
 
Ignace Vergote
No Relationships to Disclose
 
Nicole Concin
No Relationships to Disclose